<div id="readability-page-1">Mid-point pricing is the trend. AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00 – the mid-point of its range – last night. That put AgomAb Therapeutics right in step with SpyGlass Pharma (SPG) and Jennifer Garner’s Once Upon a Farm (OFRM) – both IPOs also priced at the mid-point of their respective ranges last night – after a brutal sell-off in the broad U.S. stock market. AgomAb Therapeutics NV (AGMB) priced 12.5 million American Depositary Shares (ADS) at $16.00 each to raise $200 million on Thursday night, Feb. 5, 2026. AgomAb’s ADS are expected to start trading today – Friday, Feb. 6, 2026 – on the NASDAQ. J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were the joint book-runners. AgomAb Therapeutics NV (AGMB) is developing a pill to treat people with Crohn’s disease with fibrostenosis and an inhaled treatment for people with idiopathic pulmonary fibrosis (IPF). AgomAb will use the IPO’s proceeds to finance the Phase 2 clinical trials for its leading product candidates – ontunisertib (AGMB-129) – its pill for Crohn’s disease – about $120 million earmarked from the IPO – and AGMB-447 – its inhaled treatment for pulmonary fibrosis – about $80 million from the IPO, according to the prospectus. Pfizer owned a pre-IPO stake of 5.73 percent. Pfizer will hold a 4.1 percent stake after the IPO, the prospectus said. AgomAb Therapeutics, like most biotechs at the time they go public, is not profitable: AgomAb Therapeutics reported a net loss of $65.98 million on no product revenue for the 12 months that ended Sept. 30, 2025, according to financial statements in the prospectus. (For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.</div>

AgomAb Therapeutics NV (AGMB) 的首次公開募股（IPO）定價為 16.00 美元，符合中間趨勢，通過發行 1250 萬份美國存托股票籌集了 2 億美元。這些資金將用於支持其克羅恩病藥丸和用於肺纖維化的吸入治療的二期臨牀試驗。儘管得到了輝瑞的支持，AgomAb 仍報告了 6598 萬美元的淨虧損，過去一年沒有產品收入。該股票將於納斯達克開始交易

The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’

- AgomAb Therapeutics NV (AGMB) 在 2026 年 2 月 5 日以每股 16.00 美元定價其 IPO。  
- 公司計劃利用 IPO 收益為 Crohn 病和肺纖維化的臨牀試驗融資。  
- 其在截至 2025 年 9 月的 12 個月內淨虧損 6598 萬美元。

IPO Scoop

美國制藥 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

輝瑞

標普生物技術 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

Direxion Daily Biotech Top 5 Bull 2X ETF

紐交所高增長板生物技術指數 ETF - First Trust

IPO 動態：AgomAb Therapeutics（AGMB）以 16 美元的發行價進行 IPO，並加入了 “中點俱樂部”